SCHEMBL10046329

SCHEMBL10046329

CC(C)(C)NCCOCCOCCOCCNC(=O)COCC(=O)C(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.38
ALDH1A1 P00352 2/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.31
GAA P10253 1/20 0.31
NCF1 P14598 1/20 0.30
TSHR P16473 1/20 0.30
RECQL P46063 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12980779 1.00 KDM4E (0.38) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL20993534 0.97 KDM4E (0.38) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL12981410 0.88 TSHR (0.39) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL12307356 0.88 KDM4E (0.36) KDM4EALDH1A1MEN1KMT2ANCF1
SCHEMBL24092208 0.88 KDM4E (0.32) KDM4EALDH1A1
SCHEMBL20993448 0.88 GLP1R (0.37) KDM4EALDH1A1MEN1KMT2ATSHR
SCHEMBL4402902 0.87 KDM4E (0.43) KDM4EALDH1A1MEN1KMT2AGAA
SCHEMBL20133152 0.87 KDM4E (0.43) KDM4EALDH1A1MEN1KMT2AGAA
SCHEMBL20128726 0.87 KDM4E (0.43) KDM4EALDH1A1MEN1KMT2AGAA
SCHEMBL27408407 0.87 KDM4E (0.43) KDM4EALDH1A1MEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3773750-B1 FORMULATION AND METHOD OF PREPARATION GE HEALTHCARE AS (NO) 2022-04-20 EP disclosed
WO-2019185607-A1 FORMULATION AND METHOD OF PREPARATION GE HEALTHCARE AS (NO) 2019-10-03 WO disclosed
EP-2643023-B1 RADIOIODINATION METHOD GE HEALTHCARE LTD (GB) 2018-07-18 EP disclosed
EP-2795317-B1 Composition for use in a method for cancer selection GE HEALTHCARE LTD (GB) 2018-05-30 EP disclosed
US-9956303-B2 Anti-met therapy for previously diagnosed cancer patients GE HEALTHCARE LIMITED (GB) 2018-05-01 US disclosed
EP-2680888-B1 TECHNETIUM LABELLED PEPTIDES GE HEALTHCARE LTD (GB) 2017-10-18 EP disclosed
EP-2467365-B1 RADIOIODINATION METHOD GE HEALTHCARE LTD (GB) 2017-08-09 EP disclosed
EP-2605802-B1 PEPTIDE RADIOTRACER COMPOSITIONS GE HEALTHCARE LTD (GB) 2017-04-26 EP disclosed
EP-2509638-B1 IODINE RADIOLABELLING METHOD GE HEALTHCARE LTD (GB) 2017-04-19 EP disclosed
US-20120251447-A1 RADIOIODINATED TROPANE DERIVATIVES GE HEALTHCARE LIMITED (GB) 2012-10-04 US disclosed
US-20110280806-A1 DYE CONJUGATE IMAGING AGENTS GE HEALTHCARE AS (NO) 2011-11-17 US disclosed
US-20100196282-A1 OPTICAL IMAGING AGENTS GE HEALTHCARE LIMITED (GB) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120251447-A1 RADIOIODINATED TROPANE DERIVATIVES ADRB3, TH, TBXA2R KDM4E 3479/4885ALDH1A1 834/4885MEN1 2181/4885
US-20110280806-A1 DYE CONJUGATE IMAGING AGENTS DSC1, SDCBP, DOCK5 KDM4E 3469/4885ALDH1A1 1716/4885MEN1 804/4885
US-20100196282-A1 OPTICAL IMAGING AGENTS VIP, SSTR4, NGLY1 KDM4E 3923/4885ALDH1A1 3887/4885MEN1 356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.